| # | Title | Journal | Year | Citations |
|---|
| 1 | Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology | Gastroenterology | 2014 | 277 |
| 2 | Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial | Lancet, The | 2021 | 194 |
| 3 | Global burden of inflammatory bowel disease | The Lancet Gastroenterology and Hepatology | 2020 | 187 |
| 4 | Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis | The Lancet Gastroenterology and Hepatology | 2021 | 114 |
| 5 | Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis | Gastroenterology | 2020 | 101 |
| 6 | Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium | The Lancet Gastroenterology and Hepatology | 2021 | 69 |
| 7 | Systematic review with meta‐analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease | Alimentary Pharmacology and Therapeutics | 2019 | 66 |
| 8 | HLADQA1*05 genotype predicts anti‐drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease | Alimentary Pharmacology and Therapeutics | 2020 | 60 |
| 9 | Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease | BioDrugs | 2020 | 58 |
| 10 | An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials | Gastroenterology | 2021 | 57 |
| 11 | Morbidity and Mortality After Surgery for Nonmalignant Colorectal Polyps: A 10-Year Nationwide Analysis | American Journal of Gastroenterology | 2019 | 54 |
| 12 | Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters | Molecular Pharmaceutics | 2017 | 53 |
| 13 | HLA‐DQA1‐HLA‐DRB1 polymorphism is a major predictor of azathioprine‐induced pancreatitis in patients with inflammatory bowel disease | Alimentary Pharmacology and Therapeutics | 2018 | 53 |
| 14 | Defining Quality Indicators for Best-Practice Management of Inflammatory Bowel Disease in Canada | Canadian Journal of Gastroenterology and Hepatology | 2014 | 50 |
| 15 | Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease | American Journal of Gastroenterology | 2014 | 50 |
| 16 | Acute severe ulcerative colitis: latest evidence and therapeutic implications | Therapeutic Advances in Chronic Disease | 2018 | 50 |
| 17 | Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology? | Rheumatology and Therapy | 2020 | 49 |
| 18 | Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium | The Lancet Gastroenterology and Hepatology | 2022 | 41 |
| 19 | Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease | Alimentary Pharmacology and Therapeutics | 2018 | 40 |
| 20 | Vedolizumab in Refractory Microscopic Colitis: An International Case Series | Journal of Crohn's and Colitis | 2019 | 37 |
| 21 | US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease | Inflammatory Bowel Diseases | 2019 | 34 |
| 22 | Incidence, outcomes, and impact of COVID‐19 on inflammatory bowel disease: propensity matched research network analysis | Alimentary Pharmacology and Therapeutics | 2022 | 34 |
| 23 | Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease | Current Treatment Options in Gastroenterology | 2019 | 30 |
| 24 | External Validation of the Oakland Score to Assess Safe Hospital Discharge Among Adult Patients With Acute Lower Gastrointestinal Bleeding in the US | JAMA Network Open | 2020 | 30 |
| 25 | IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease? | Bailliere's Best Practice and Research in Clinical Gastroenterology | 2019 | 28 |
| 26 | Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016 | Inflammatory Bowel Diseases | 2022 | 28 |
| 27 | Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease | American Journal of Gastroenterology | 2022 | 28 |
| 28 | Computer-Based Virtual Reality Colonoscopy Simulation Improves Patient-Based Colonoscopy Performance | Canadian Journal of Gastroenterology and Hepatology | 2014 | 27 |
| 29 | Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005–2016) | Clinical Gastroenterology and Hepatology | 2020 | 27 |
| 30 | Impact of Public Health Policies on Alcohol‐Associated Liver Disease in Latin America: An Ecological Multinational Study | Hepatology | 2021 | 27 |
| 31 | Outcome measures in clinical trials of treatments for acute severe haemorrhage | Trials | 2018 | 25 |
| 32 | Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | Journal of Crohn's and Colitis | 2019 | 25 |
| 33 | Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial | BMJ Open | 2019 | 25 |
| 34 | The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas | The Lancet Gastroenterology and Hepatology | 2022 | 25 |
| 35 | Outcomes of Computed Tomography and Magnetic Resonance Enterography in Clinical Practice of Inflammatory Bowel Disease | Digestive Diseases and Sciences | 2014 | 24 |
| 36 | Malnutrition Matters in Canadian Hospitalized Patients | Nutrition in Clinical Practice | 2015 | 24 |
| 37 | Cluster over individual randomization: are study design choices appropriately justified? Review of a random sample of trials | Clinical Trials | 2020 | 24 |
| 38 | Opioid use is associated with decreased quality of life in patients with Crohn′s disease | Saudi Journal of Gastroenterology | 2014 | 23 |
| 39 | Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease | Digestive Diseases and Sciences | 2020 | 23 |
| 40 | Epidemiology and Natural History of Perianal Crohn’s Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts | Inflammatory Bowel Diseases | 2022 | 23 |
| 41 | Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis | Gastroenterology | 2022 | 23 |
| 42 | Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis | Clinical Gastroenterology and Hepatology | 2020 | 22 |
| 43 | High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists | Scientific Reports | 2022 | 22 |
| 44 | Developing a framework for the ethical design and conduct of pragmatic trials in healthcare: a mixed methods research protocol | Trials | 2018 | 21 |
| 45 | Movement Disorders Associated With Hemochromatosis | Canadian Journal of Neurological Sciences | 2016 | 19 |
| 46 | What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity? | Bailliere's Best Practice and Research in Clinical Gastroenterology | 2019 | 19 |
| 47 | How Do We Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission? | Clinical Gastroenterology and Hepatology | 2020 | 19 |
| 48 | Trends in the Economic Burden of Chronic Liver Diseases and Cirrhosis in the United States: 1996–2016 | American Journal of Gastroenterology | 2021 | 19 |
| 49 | Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn’s Disease | Clinical Gastroenterology and Hepatology | 2020 | 17 |
| 50 | Patients With Low Drug Levels or Antibodies to a Prior Anti–Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti–Tumor Necrosis Factor | Clinical Gastroenterology and Hepatology | 2022 | 17 |
